(1 - 19 von 23
)
VolitionRX Signs Collaboration Agreement With Stefan ...
www.finanznachrichten.de
SINGAPORE, July 9, PRNewswire/ -- VolitionRX Limited (OTC:VNRX.OB), a life sciences company focused on developing blood-based diagnostic tests, is …
Dr. Stefan Holdenrieder Archives - Lung Cancer News Today
lungcancernewstoday.com
VolitionRx Limited has announced that its Nucleosomics platform technology for the diagnosis of lung cancer will be evaluated in a confirmatory clinical study by ...
VolitionRx Extends Agreement With University Hospital Bonn to Include...
www.wallstreet-online.de
The CE mark performance evaluation will be led by Priv-Doz. Dr. Stefan Holdenrieder at the Institute of Clinical Chemistry and Clinical Pharmacology, University
Biomarkers are diagnostic game changers
healthcare-in-europe.com
Providing insights into new cardiac testing methods, Professor Stefan Holdenrieder, Director of the Institute of Laboratory Medicine at Munich’s German Heart...
Creating the essential link
healthcare-in-europe.com
While clinical labs and lab IT solutions appear to be able to meet current requirements, biobanking presents a whole new world of challenges to data flows and...
4. Onkologisches Symposium der Trillium AkademieBUNDESVERBAND DEUTSCHER PATHOLOGEN e.V.
www.pathologie.de
Stefan Holdenrieder (Deutsches Herzzentrum München). Personalisierte Krebsmedizin – State of the Art und Zukunftsperspektiven Vorsitz Prof. Dr. med.
Neuer Marker für Schäden im Herzvorhof entdeckt - TUM
www.tum.de
... Nazan Puluca, Isabel Deisenhofer, Sophia Doll, Stefan Holdenrieder, Matthias Mann, Rüdiger Lange, Markus Krane: Myosin binding protein ...
Gründung Steinbeis-UnternehmenSteinbeis-Transferzentrum
www.steinbeis.de
— Dr. med. Stefan Holdenrieder ist Leiter des neu gegründeten Steinbeis-Forschungszentrums BioCoDE Biomarker Consulting & Data Evaluation, das ...
VolitionRX Signs Collaboration Agreement With Stefan ...cloudfront.net
d1io3yog0oux5.cloudfront.net
— With Stefan Holdenrieder of Rheinische. Friedrich-Wilhelms-Universitat Bonn. Germany. Company to Host Virtual Road Show Conference Call ...
WHO Classification of TumoursWorld Health Organization
events.iarc.who.int
— Stefan Holdenrieder – IC3R initiatives. Ian Cree & Nick Myles – Panel discussion. All –
Schwerpunkt - Trillium GmbH Medizinischer Fachverlag
www.trillium.de
Prof. Dr. med. Stefan Holdenrieder Universitätsklinik Bonn Stefan.Holdenrieder[at]uni-bonn[dot]de. Literatur · Liquid Profiling aus Sicht der Labormedizin
Warum Biomarker in der Diagnostik unverzichtbar sindhealthcare-in-europe.com
healthcare-in-europe.com
— Stefan Holdenrieder, Leiter des Instituts für Laboratoriumsmedizin am Deutschen Herzzentrum in München, berichtet im Interview mit European ...
Sysmex Inostics OncoBEAM™ circulating tumor DNA technology...
www.sysmex-europe.com
Sysmex corporate press releases
VolitionRx Inks Deal to Validate Technology, Secure Cancer Trials |...
www.360dx.com
The agreement is to support the company’s analytical and preanalytical research and assist in its trials aimed at a number of cancers.
VolitionRx Announces First Published Data in Anticancer Research...
www.irdirect.net
... by Dr. Stefan Holdenrieder at the Institute of Clinical Chemistry and ... website (www.volitionrx.com) or connect with us on Twitter, LinkedIn, ...
VolitionRx Expands Scientific Advisory Board
www.streetinsider.com
Dr. Stefan Holdenrieder, a senior physician and chemical ... website (http://www.volitionrx.com) or connect with us via Twitter, LinkedIn, ...
VolitionRx Extends Agreement With University Hospital Bonn
www.globenewswire.com
Dr. Stefan Holdenrieder at the Institute of Clinical Chemistry and ... (www.volitionrx.com) or connect with us via Twitter, LinkedIn or Facebook.
sortiert nach Relevanz / Datum